Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS · Real-Time Price · USD
0.656
+0.003 (0.49%)
At close: Apr 28, 2026, 4:00 PM EDT
0.660
+0.003 (0.52%)
Pre-market: Apr 29, 2026, 4:32 AM EDT
Fractyl Health Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
100
Market Cap
104.12M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Q32 Bio | 53.74M |
| Coya Therapeutics | 7.95M |
| Rani Therapeutics Holdings | 1.63M |
| Coeptis Therapeutics Holdings | 1.36M |
| NRx Pharmaceuticals | 1.23M |
| Inovio Pharmaceuticals | 65.34K |
GUTS News
- 5 weeks ago - Fractyl Health Earnings Call Transcript: Q4 2025 - Transcripts
- 6 weeks ago - Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026 - GlobeNewsWire
- 2 months ago - Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance - GlobeNewsWire
- 3 months ago - Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS - Business Wire
- 3 months ago - Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product - Benzinga
- 3 months ago - Fractyl Health Transcript: Study result - Transcripts
- 3 months ago - Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation - GlobeNewsWire
- 4 months ago - Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness - GlobeNewsWire